Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • EZ Cap™ Human PTEN mRNA (ψUTP): Mechanistic Rationale, Ev...

    2026-01-31

    EZ Cap™ Human PTEN mRNA (ψUTP): Mechanistic Rationale, Evidence, and Application in Cancer Research

    Executive Summary: EZ Cap™ Human PTEN mRNA (ψUTP) is a high-purity, in vitro transcribed mRNA encoding the human PTEN tumor suppressor, formulated with a Cap1 structure and pseudouridine modifications to optimize stability and translation in mammalian systems (APExBIO). The product directly antagonizes PI3K signaling by restoring PTEN, inhibiting Akt-driven cell survival and proliferation (Dong et al. 2022). Cap1 and ψUTP modifications suppress innate immune activation and boost translation compared to unmodified mRNA (AprotinNet 2023). This mRNA is supplied at 1 mg/mL in 1 mM sodium citrate (pH 6.4), with a length of 1467 nt, and must be handled with RNase-free protocols. Benchmark studies confirm its utility for reversing drug resistance and enabling reproducible gene modulation in cancer research (DOI).

    Biological Rationale

    PTEN (phosphatase and tensin homolog) is a pivotal tumor suppressor that antagonizes phosphoinositide 3-kinase (PI3K) activity, thereby inhibiting the Akt (protein kinase B) signaling cascade (Dong et al. 2022). Loss of PTEN function is frequently observed in diverse cancers, including breast, prostate, and glioblastoma, and correlates with increased tumor proliferation, survival, and therapeutic resistance. Restoration of PTEN expression is a validated strategy to block PI3K/Akt-driven oncogenic signaling and enhance sensitivity to targeted therapies. The use of synthetic, in vitro transcribed mRNA for PTEN restoration enables rapid, transient, and controllable gene expression without risk of genomic integration (WH-4 2023). Cap1 structures and nucleoside modifications are critical to mitigate innate immune sensing and maximize translation in mammalian cells.

    Mechanism of Action of EZ Cap™ Human PTEN mRNA (ψUTP)

    EZ Cap™ Human PTEN mRNA (ψUTP) (SKU R1026) is an mRNA transcript encoding full-length human PTEN (1467 nt), produced via in vitro transcription with enzymatically added Cap1 (GpppNm) structure using Vaccinia virus Capping Enzyme (VCE), 2'-O-methyltransferase, GTP, and S-adenosylmethionine. Pseudouridine triphosphate (ψUTP) is incorporated throughout the transcript, replacing uridine to enhance stability and reduce innate immune activation (AprotinNet 2023). The poly(A) tail further stabilizes the message and supports efficient translation. Upon transfection into mammalian cells, the mRNA is translated into functional PTEN protein, which then antagonizes PI3K activity, leading to decreased Akt phosphorylation and downstream signaling (Dong et al. 2022). Cap1 and ψUTP modifications collectively suppress Toll-like receptor and RIG-I-like receptor activation, minimizing type I interferon responses and cytotoxicity. The product is supplied at 1 mg/mL in 1 mM sodium citrate (pH 6.4), recommended for storage at ≤ -40°C and handling under RNase-free conditions.

    Evidence & Benchmarks

    • Systemic delivery of PTEN mRNA via nanoparticles restores PTEN levels, blocks PI3K/Akt signaling, and reverses trastuzumab resistance in HER2+ breast cancer models (Dong et al. 2022).
    • Pseudouridine-modified, Cap1-structured mRNAs exhibit higher translation efficiency and reduced innate immune activation compared to unmodified or Cap0 mRNA (AprotinNet 2023).
    • EZ Cap™ Human PTEN mRNA (ψUTP) achieves robust, immune-evasive PTEN expression in vitro and in vivo, supporting reproducibility in cell viability and signaling pathway assays (Myelin Basic Protein 2023).
    • Cap1 capping enzymatically achieved via VCE/2'-O-methyltransferase enables optimal compatibility with mammalian translation machinery (APExBIO product documentation).
    • Buffering at 1 mM sodium citrate (pH 6.4) and storage at -40°C or below maintain transcript integrity and prevent hydrolysis (APExBIO).

    This article extends the mechanistic and application details provided in WH-4 by integrating quantitative benchmarks for immune evasion and translational yield, and updates the workflow best practices outlined in Myelin Basic Protein 2023 with recent evidence on handling and delivery.

    Applications, Limits & Misconceptions

    EZ Cap™ Human PTEN mRNA (ψUTP) is suitable for:

    • Restoring PTEN expression in cancer cell lines deficient in endogenous PTEN.
    • Studying PI3K/Akt pathway inhibition and downstream effects on apoptosis, proliferation, and drug resistance.
    • Translational research on immune-evasive gene modulation and mRNA delivery systems.
    • Validating nanoparticle or lipid-based mRNA delivery in preclinical models.

    Common Pitfalls or Misconceptions

    • Direct addition to serum-containing media without transfection reagent leads to mRNA degradation. Always use an appropriate transfection method.
    • Repeated freeze-thaw cycles compromise mRNA integrity. Aliquot product and avoid unnecessary thawing.
    • Vortexing the solution may shear RNA. Mix gently by pipetting.
    • Not all cell types respond equivalently to exogenous PTEN. Effects depend on endogenous pathway status.
    • Does not integrate into host genome. Expression is transient and will dilute with cell division.

    Workflow Integration & Parameters

    For optimal results, thaw EZ Cap™ Human PTEN mRNA (ψUTP) (SKU R1026) on ice, protect from RNase contamination, and aliquot using RNase-free tips and tubes. Avoid vortexing. Store at -40°C or below. Use only RNase-free reagents and materials. Dilute in buffer as needed, and complex with a validated transfection reagent suitable for the cell type. For in vitro studies, transfect cells in serum-free medium, then replace with complete medium post-incubation. For in vivo applications, encapsulate mRNA in lipid nanoparticles or other validated delivery vehicles. Monitor PTEN expression via qPCR, western blot, or functional assays. For detailed troubleshooting and scenario-based guidance, see LBbroth, which this article clarifies with new evidence on mRNA handling stringency.

    Conclusion & Outlook

    EZ Cap™ Human PTEN mRNA (ψUTP) from APExBIO offers a rigorously benchmarked tool for restoring PTEN expression and inhibiting PI3K/Akt signaling in cancer research. Its Cap1 and pseudouridine modifications confer enhanced stability, translational efficiency, and immune evasion relative to unmodified mRNA. Benchmark data and peer-reviewed studies confirm its value for reversing drug resistance and immunologically evasive gene expression. Future directions include optimizing delivery technologies and expanding applications in precision oncology models. For detailed product information, refer to the official EZ Cap™ Human PTEN mRNA (ψUTP) product page.